Raskov et al. indicated (Raskov et al., 2021) that CD8+ T cells play a crucial role in immunotherapy, and the relative enrichment of CD8+ T cells in the low-risk group facilitates an effective anti-tumor response. This evidence concerns the gene CD8A and neoplasm.